PRAXIS BIOLOGICS AND CYANAMID WILL CONJUGATE IN DEAL WORTH OVER $ 200 MIL.; VACCINE FIRM'S CORE ANTIGEN TECHNOLOGY COMPLEMENTS LEDERLE PIPELINE

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".